

EFFICACY AND SAFETY OF STELFONTA® (tigilanol tiglate injection) 1 mg/mL AS AN INTRATUMORAL TREATMENT FOR CANINE MAST CELL TUMORS

OBJECTIVES

A randomized, blinded, controlled field clinical study explored the efficacy and tolerability of intratumoral administration of tigilanol tiglate for the treatment of canine mast cell (MCT)

MATERIALS & METHODS


- **Animals:**
 - 123 dogs, with stage Ia or IIIa cutaneous or lower limb subcutaneous MCT confirmed by fine needle aspiration cytology.
 - Dogs randomised into 81 tigilanol tiglate treatment dogs and 42 control treatment dogs.
- **Treatment administration:**
 - Concurrent medications: Corticosteroids, H1 & H2 blockers.
 - Tigilanol tiglate: 0.5mg of tigilanol tiglate delivered per cm³ of MCT volume.
- **Evaluations:**
 - Complete response (CR; disappearance of the target lesion).
 - Safety and wound healing.

RESULTS

- 75% (60/80) of the treated dogs achieved complete resolution at Day 28 vs 5% (2/38) in control dogs. A second tigilanol tiglate treatment for 18 dogs that did not achieve CR at 28 days increased overall response rate to 87%.
- 96% (55/57) of treated dogs had no local recurrence of disease 84 days after treatment.
- The most frequent adverse events were reactions at the treatment site: 92.5% (74/80) of treated dogs developed wounds that healed rapidly from Day 7.

CLINICAL INTEREST

Tigilanol tiglate is highly effective for the treatment of MCT in dogs and is well tolerated.



REFERENCES

- Wiest ML, Geller S, Pittenger ST, Burke-Schwarz C, Johannes, Chad M, Reddell PW, et al. Controlled, Randomised Study of Intratumoural Tigilanol Tiglate (EBC-46) for Treatment of Canine Mast Cell Tumours. In: ACVIM Forum 2019 [Internet]. 2019.
- Wiest ML, Geller S, Pittenger ST, Burke-Schwarz C, Johannes, Chad M, Reddell PW, et al. Controlled, Randomised Study of Intratumoural Tigilanol Tiglate (EBC-46) for Treatment of Canine Mast Cell Tumours. In: ESVONC annual Congress proceedings, Frankfurt, 2019, p62.